{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:43:13Z","timestamp":1790095393047,"version":"4.0.1"},"reference-count":82,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most frequent subtype of NETs and their incidence has steadily increased over the past few decades. Patients with GEP-NETs often experience a large symptom burden and decrease in quality of life. Delays in diagnosis and high incidence of metastatic disease are the consequences of a lack of awareness or a lack of understanding of how to manage GEP-NETs among health care professionals. Although surgical resection is the only curative approach for GEP-NETs, many patients are not candidates for surgery. For these patients, new therapies have emerged recently, including radiolabeled therapeutic peptides used to target cancer cells and inhibit tumor growth. Radiolabeled somatostatin analogs, such as [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-TATE (\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE), are often used in radioligand therapy (RLT).\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTATATE has been approved for the treatment of advanced GEP-NETs and has demonstrated efficacy and safety in clinical trials as well as in real-world studies. With the emergence of RLT for the management of GEP-NETs, treatment sequencing is of increasing importance. Considering the perspectives of patients with GEP-NETs on using RLT in their treatment journey is not only key to understanding and allaying their concerns regarding the safety of RLT but is also important in helping to identify patient priorities of treatment attributes. This review aims to identify the factors influencing patients considering RLT, their perceptions regarding treatment sequence options, the barriers in RLT access, and the disparities (eg, racial, geographical) among patients with GEP-NETs in accessing care.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00474","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:59:26Z","timestamp":1762462766000},"page":"562-572","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-6557","authenticated-orcid":true,"given":"Mark","family":"Lewis","sequence":"first","affiliation":[{"name":"Intermountain Health, Sandy, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumor Research Foundation, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5883-6775","authenticated-orcid":true,"given":"Lisa","family":"Yen","sequence":"additional","affiliation":[{"name":"Neuroendocrine Cancer Foundation (formerly LACNETS), Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.09.002"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24750"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.017"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i47.8123"},{"key":"e_1_3_6_8_2","first-page":"29","article-title":"Gastroenteropancreatic neuroendocrine tumors: Diagnosis and treatment","volume":"26","author":"D\u00edez M","year":"2013","unstructured":"D\u00edez M, Teul\u00e9 A, Salazar R: Gastroenteropancreatic neuroendocrine tumors: Diagnosis and treatment. Ann Gastroenterol 26:29-36, 2013","journal-title":"Ann Gastroenterol"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2207829"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0066-3"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112975"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00007"},{"key":"e_1_3_6_13_2","first-page":"347","article-title":"Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues","volume":"14","author":"Bodei L","year":"2010","unstructured":"Bodei L, Pepe G, Paganelli G: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci 14:347-351, 2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.941832"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2011.06.009"},{"key":"e_1_3_6_16_2","first-page":"1","article-title":"Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond","volume":"42","author":"Gafita A","year":"2022","unstructured":"Gafita A, Marcus C, Kostos L, et al: Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am Soc Clin Oncol Educ Book 42:1-17, 2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030114"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2006.01.001"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07246-7"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00701-3"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000818"},{"key":"e_1_3_6_24_2","article-title":"Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: Results from the first global survey of patients with NETs","author":"Singh S","unstructured":"Singh S, Granberg D, Wolin E, et al: Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: Results from the first global survey of patients with NETs. JCO Glob Oncol 10.1200\/JGO.2015.002980","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13310"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.32381"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13138"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6412-8"},{"key":"e_1_3_6_29_2","first-page":"14","article-title":"An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: The diagnostic approach","volume":"69","author":"Kuiper P","year":"2011","unstructured":"Kuiper P, Verspaget HW, Overbeek LI, et al: An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: The diagnostic approach. Neth J Med 69:14-20, 2011","journal-title":"Neth J Med"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10567-1"},{"key":"e_1_3_6_31_2","first-page":"35","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: Current development, challenges, and clinical perspectives","volume":"11","author":"Zhang XB","year":"2024","unstructured":"Zhang XB, Fan YB, Jing R, et al: Gastroenteropancreatic neuroendocrine neoplasms: Current development, challenges, and clinical perspectives. Mil Med Res 11:35, 2024","journal-title":"Mil Med Res"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.11.1417"},{"key":"e_1_3_6_33_2","article-title":"Living with neuroendocrine tumors: Assessment of quality of life through a mobile application","author":"Adams JR","unstructured":"Adams JR, Ray D, Willmon R, et al: Living with neuroendocrine tumors: Assessment of quality of life through a mobile application. JCO Clin Cancer Inform 10.1200\/CCI.19.00025","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0455"},{"key":"e_1_3_6_36_2","unstructured":"US Food and Drug Adminstration: FDA approves Xermelo for carcinoid syndrome diarrhea. 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-xermelo-carcinoid-syndrome-diarrhea"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.5865"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.258897"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i25.3686"},{"key":"e_1_3_6_40_2","volume-title":"LUTATHERA\u00ae Prescribing Information","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration: LUTATHERA\u00ae Prescribing Information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0459-4"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-016-0157-0"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100574"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.12113"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001795"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2023.00141"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298824"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05771-3"},{"key":"e_1_3_6_49_2","article-title":"Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs)","volume":"39","author":"Casas EAJ","year":"2021","unstructured":"Casas EAJ, Martinez NP, Herranz UA, et al: Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). J Clin Oncol 39, 2021 (suppl 3; abstr 364)","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184506"},{"key":"e_1_3_6_51_2","first-page":"264043","article-title":"Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant (225)Ac-DOTATATE targeted alpha therapy and capecitabine: A real-world scenario management based long-term outcome study","volume":"122","author":"Ballal S","year":"2022","unstructured":"Ballal S, Yadav MP, Tripathi M, et al: Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant (225)Ac-DOTATATE targeted alpha therapy and capecitabine: A real-world scenario management based long-term outcome study. J Nucl Med 122:264043, 2022","journal-title":"J Nucl Med"},{"key":"e_1_3_6_52_2","first-page":"1330","article-title":"Patient-defined goals and preferences among adults with advanced neuroendocrine tumors","volume":"20","author":"Li D","year":"2022","unstructured":"Li D, Sun CL, Kim H, et al: Patient-defined goals and preferences among adults with advanced neuroendocrine tumors. J Natl Compr Canc Netw 20:1330-1337.e3, 2022","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.7_suppl.75"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1159\/000516015"},{"key":"e_1_3_6_55_2","unstructured":"National Library of Medicine: Comparing retreatment of 177Lu-DOTATATE PRRT versus everolimus in patients with metastatic unresectable midgut neuroendocrine tumors NET RETREAT trial. 2025. https:\/\/clinicaltrials.gov\/study\/NCT05773274"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32678"},{"key":"e_1_3_6_59_2","unstructured":"US Food and Drug Administration: FDA approves Pluvicto for metastatic castration-resistant prostate cancer. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT254"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS514"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00071"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01046-6"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031229"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-019-00103-2"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25662"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1220"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-0912-1"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.16.1973"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08359-z"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e18081"},{"key":"e_1_3_6_72_2","first-page":"125","article-title":"Survival disparities in rural versus urban patients with pancreatic neuroendocrine tumor: A multi-institutional study from the US neuroendocrine tumor study group","volume":"233","author":"Mirza MB","year":"2024","unstructured":"Mirza MB, Baechle JJ, Marincola Smith P, et al: Survival disparities in rural versus urban patients with pancreatic neuroendocrine tumor: A multi-institutional study from the US neuroendocrine tumor study group. Am J Surg 233:125-131, 2024","journal-title":"Am J Surg"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00174"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32607"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29338"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.PANCA22-PR002"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0093"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106740"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.123927"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2215609"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.05339.x"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.2021.0126"},{"key":"e_1_3_6_83_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5986-0"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:08:14Z","timestamp":1778713694000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1200\/OP-25-00474"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00474","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}